Regeneron Pharmaceuticals (REGN) : On Friday, The money flowed into the Regeneron Pharmaceuticals (REGN) stock with an uptick to downtick ratio was recorded at 1.64. Transactions worth $12.3 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $7.5 million. The total money flow into the stock was $4.8 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0 million of block transactions on upticks. The total money flow in block trades was $0 million. In terms of price action, Regeneron Pharmaceuticals (REGN) traded down $0.74 during the session at $388.78. Compared to the previous days closing, the stock was down only by -0.19%. For the week, the stock is 4%, over previous weeks closing.
Regeneron Pharmaceuticals (REGN) : The highest short term price target forecast on Regeneron Pharmaceuticals (REGN) is $668 and the lowest target price is $325. A total of 18 equity analysts are currently covering the company. The average price of all the analysts is $487.5 with a standard deviation of $82.33.
Regeneron Pharmaceuticals (NASDAQ:REGN): stock turned positive on Friday. Though the stock opened at $391.4, the bulls momentum made the stock top out at $392.6 level for the day. The stock recorded a low of $387.43 and closed the trading day at $391.34, in the green by 0.47%. The total traded volume for the day was 477,812. The stock had closed at $389.52 in the previous days trading.
In a related news,The director of Regeneron Pharmaceuticals Inc, Ryan Arthur F sold 1,000 shares at $396.64 on May 24, 2016. The Insider selling transaction had a total value worth of $396,640. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.